Table 2.
Risk stratification of patients with myelofibrosis (MF) according to the International prognostic scoring system (IPSS; [3]), dynamic IPSS (DIPSS), [4], and DIPSS plus [21]. (Table adjusted from [27])
| Risk category | Scale | Estimated survival (years) |
|---|---|---|
| IPSS | No. of risk factors a | Median (95% CI) |
| Low | 0 | 11.3 (9.8–15.1) |
| Intermediate-1 | 1 | 7.9 (6.6–9.5) |
| Intermediate-2 | 2 | 4.0 (3.6–4.9) |
| High | ≥3 | 2.3 (1.9–2.6) |
| DIPSS | Prognostic score b | Median |
| Low | 0 | NR |
| Intermediate-1 | 1 or 2 | 14.2 |
| Intermediate-2 | 3 or 4 | 4.0 |
| High | 5 or 6 | 1.5 |
| DIPSS plus | Prognostic score c | Median |
| Low | 0 | 15.4 |
| Intermediate-1 | 1 | 6.5 |
| Intermediate-2 | 2 or 3 | 2.9 |
| High | 4–6 | 1.3 |
NR not reached
aRisk factors include age >65 years, constitutional symptoms (defined as weight loss >10% of baseline value in the year preceding diagnosis and/or unexplained fever or excessive sweats persisting for more than 1 month), hemoglobin <10 g/dl, white blood cell count >25 × 109/l, and peripheral blood blasts ≥1%
bRisk factors include age >65 years (1 point), constitutional symptoms (1 point), hemoglobin <10 g/dl (2 points), white blood cell count >25 × 109/l (1 point), and peripheral blood blasts ≥1% (1 point)
cScoring is based on DIPSS risk categories (low risk, 0 points; intermediate-1 risk, 1 point; intermediate-2 risk, 2 points; high risk, 3 points) and additional risk factors (unfavorable karyotype, 1 point; platelet count <100 × 109/l, 1 point; transfusion need, 1 point)